Trial reportProceedings of the National Academy of Sciences of the United States of America2011
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.The pharmacogenomics journal · 2016Pooled it
- Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.BMC medicine · 2013Pooled it
- Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.Scientific reports · 2016Trial
- A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.Liver international : official journal of the International Association for the Study of the Liver · 2016Trial
- Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.Clinical and molecular hepatology · 2018Article
- A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications.Viruses · 2018Review
- High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.The Kaohsiung journal of medical sciences · 2017Article
- IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.Antiviral therapy · 2015Article
- Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.Journal of biomedical research · 2014Article
- The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin.Hepatitis monthly · 2014Article
- Individualization of chronic hepatitis C treatment according to the host characteristics.World journal of gastroenterology · 2014Review
- Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis.Hepatitis monthly · 2014Article
- Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.Mathematical biosciences · 2013Article
- Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients.Hepatology international · 2013Article
- Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews.Molecular & cellular proteomics : MCP · 2013Article
- Viral hepatitis C gets personal--the value of human genomics to public health.Public health genomics · 2013Review
- Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.PloS one · 2013Article
- Genetics of IL28B and HCV--response to infection and treatment.Nature reviews. Gastroenterology & hepatology · 2012Review
- Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Experimental and therapeutic medicine · 2012Article
- The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.Clinical & developmental immunology · 2012Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asian patients with chronic hepatitis C (CHC) are known to have better virological responses to pegylated (Peg) IFN-based therapy than Western patients. Although IL28B gene polymorphisms may contribute to this difference, whether favorable hepatitis C virus (HCV) kinetics during treatment plays a role remains unclear. We enrolled 145 consecutive Taiwanese patients with CHC receiving Peg-IFN α-2a plus ribavirin for the study. Blood samples were taken more frequently at defined intervals in the first 3 d. Peg-IFN was administered at week 1. It was then administered weekly in combination with daily ribavirin for 24 or 48 wk. A mathematical model fitted to the observed HCV kinetics was constructed, which could interpret the transient HCV titer elevation after Peg-IFN treatment. The results demonstrated a comparable viral clearance rate (c = 3.45 ± 3.73) (day(-1), mean ± SD) but lower daily viral production rate (P = 10(6)-10(12)) in our patients than those reported previously in Western patients. Of 110 patients with a sustained virological response (SVR), 47 (43%) had a transient elevation of viral titer within 12 h (proportion of 12 h/3 d: 44% in non-SVR vs. 70% in SVR; P = 0.029). Among 91 patients with available rs8099917 data, patients with the TT genotype had an early surge of viral titer after therapy and a higher SVR and viral clearance rate than those with the GT genotype. In conclusion, Taiwanese patients with CHC receiving Peg-IFN plus ribavirin therapy have a lower daily viral production rate than Western patients, and the rs8099917 TT genotype may contribute to the increased viral clearance rate and better virological responses in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.